Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
524 Leser
Artikel bewerten:
(2)

Azentio Software Pvt Ltd: Azentio Software announces Aliza Knox as new Board Member

Finanznachrichten News

SINGAPORE, Jan. 24, 2022 /PRNewswire/ -- Azentio Software ("Azentio"), a global information technology company, is pleased to announce the appointment of Aliza Knox as a Non-Executive Director to the Board.

Azentio Software announces Aliza Knox as new Board Member

Aliza brings to Azentio a wealth of knowledge and expertise with over three decades of broad international marketing and management experience. She is most recognized for building and operating successful businesses in complex and emerging sectors including financial services, consulting, mobile, SaaS, while covering markets across Asia, Latin America, and Europe.

Aliza has held several leadership roles in relationship development, sales and operations, as well as strategic partnering. Most recently, Aliza was Head of APAC for Cloudflare and previously was Chief Operating Officer at Unlockd. In an earlier role, she held the position of Head of APAC for Twitter, having joined the digital enterprise after Google, where she was Managing Director of Online Sales & Operations in APAC. Aliza has extensive financial services experience at eminent companies like Visa International and Charles Schwab Corporation. She was the Vice President and Director - Asian Financial Services at Boston Consulting Group.

Aliza has served on the boards of listed companies in Australia, Singapore, Germany and UK. She was an advisor to the ANZ Bank Board Technology Committee. As a Non-Executive Board Director and advisor, she is dedicated to empowering the next generation of leaders, to build successful global businesses. As one way to do this, she has written the forthcoming book 'Don't Quit Your Day Job' (Wiley; April 2022).

Commenting on Aliza's appointment, Tony Kinnear, Chief Executive Officer, Azentio Software, said, "We welcome Aliza to our Board. Her extensive operational experience as a senior executive in marquee global firms and her knowledge and insights in customer-driven technology businesses will add depth to the Board's competencies as we continue to execute on our ambitious growth plans and drive value for our clients."

"I am honoured to be joining Azentio at such a challenging and exciting time," stated Aliza Knox. "As someone who is passionate about technology, I am confident and excited about the direction that Azentio is taking. I look forward to working with the Board and the talented leadership team on accelerating our core business initiatives and shaping a robust, sustainable growth path for Azentio," she said.

About Azentio Software Private Ltd

Azentio Software provides mission critical, core and vertical-specific software products for clients in banking, financial and insurance services primarily across the Middle East and Africa, Asia Pacific, and India. The company's flagship products include Premia Astra and Beyontec Suite (Core Insurance Software), Kastle (Universal Banking Solution), iMAL (Islamic Core Banking Platform), AMLOCK (Financial Crime Detection and Management Solution), MFund Plus (Wealth & Asset Management Solution) and Orion (Enterprise Resource Planning Solution). More details can be found here azentio.com/

Media Contact:
Danielle Karam
danielle.karam@azentio.com

Photo: https://mma.prnewswire.com/media/1731440/Aliza_Knox.jpg
Logo: https://mma.prnewswire.com/media/1712686/Azentio_Software_Logo.jpg

(PRNewsfoto/Azentio Software Pvt Ltd)

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.